AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03009877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Premium Video Intubation Platform-KARL STORZ
Description: After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
Study NCT03857516 — intervention group
Intervention type: DEVICE
Intervention: Multipolar left ventricular lead implantation
Description: Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
Study NCT00940966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: energy restricted very-low carbohydrate diet
Description: energy restricted very-low carbohydrate diet
Study NCT00940966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic diet
Description: restricted ketogenic diet
Study NCT03580434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-STRUT
Description: Minimally invasive implantation of V-STRUT
Study NCT03748576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedicine: management through WeChat group chat
Description: Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
Study NCT00864825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
Study NCT00864825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
Study NCT00124202 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a fatty meal
Description: Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
Study NCT02822573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil 5 mg
Description: Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Study NCT02822573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
Study NCT01946893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
Study NCT01946893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
Study NCT03756727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
Study NCT03756727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
Study NCT00003134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT02054598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid and navigation
Description: Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
Study NCT01177709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
Study NCT03247465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image Fusion
Description: Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
Study NCT04513080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-chat psychotherapy (VCP)
Description: Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
Study NCT04513080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy (MBP)
Description: Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
Study NCT04513080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy with monthly video chat (Premium Plan)
Description: The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
Study NCT04513080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message-based psychotherapy with weekly video chat (Ultimate Plan)
Description: The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
Study NCT01963377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2 through nasal cannulae
Description: supplementation of O2 through nasal cannulae during bronchoscopy
Study NCT01963377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: O2-channel
Description: supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
Study NCT03287284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Low Level Laser Therapy
Description: Active application of Low Level Laser Therapy with a dose of 240 Joules
Study NCT03287284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Resistance Training
Study NCT03287284 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Resistance Training
Study NCT03287284 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Level Laser Therapy
Description: Placebo application of Low Level Laser Therapy
Study NCT05234086 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: InbioDerm + C plus advanced healing
Description: For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
Study NCT05234086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced healing
Description: Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
Study NCT02683044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)
Description: Sessions of shocks to the body of the penis
Study NCT02683044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)
Description: Sessions of shocks to the body of the penis
Study NCT03442478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2D/3D Tomosynthesis
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium For abdomen
Description: Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium For abdomen
Description: Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium For abdomen
Description: Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium For lower back
Description: Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium For lower back
Description: Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium For lower back
Description: Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 12
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 24
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 120 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 250 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 500 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 750 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 1000 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 1250 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: placebo
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: low dose group 1
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: high dose group 1
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: low dose group 2
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: high dose group 2
Study NCT02929550 — intervention group
Intervention type: OTHER
Intervention: Well-controlled
Description: Both groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l
Study NCT01090908 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Study NCT01211236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of wound dressing made of bio-bags (vitapads) containing maggots
Study NCT01211236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: application of classical hydrogel/alginate wound dressing
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subcutaneously at Week 36
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 36
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Study NCT01797341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02149602 — intervention group
Intervention type: RADIATION
Intervention: Intensity modulated radiotherapy
Description: Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 12
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
Study NCT02123615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Gammagard subdermally at Week 24
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.